Company / EPS (Diluted)
Kymera Therapeutics, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.52
FY2025
5-year range
-$24.28 / -$2.09
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
#140 of 204
Health Care
What the data says
At $-2.52, Kymera Therapeutics, Inc.'s eps (diluted) ranks #140 of 204 in the Health Care sector. Declined from $-2.09 to $-2.52 over the past 2 years.
Based on SEC 10-K filings.
-2.52 in FY2025.
Declined from $-2.09 to $-2.52 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#140 of 204 in Health CareTop 69% of 204This company -$2.52 Sector average -$0.98
▼
-157.2% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 12.2% year-over-year.
- Ranks #140 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.52 | +12.2% |
| FY2024 | -$2.87 | -37.3% |
| FY2023 | -$2.09 | +33.7% |
| FY2022 | -$3.15 | +87.0% |
| FY2021 | -$24.28 | +0.0% |
| FY2020 | -$24.28 | - |
| FY2019 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026